In pancreatic cancer, the use of a novel Epac-specific inhibitor (ESI-09), specifically inhibited Epac1-mediated Rap1 activation, ultimately resulting in impaired migration and invasion capability of cancer cells [114]. This evidence concerns the gene RAPGEF3 and familial pancreatic carcinoma.